Ripple Therapeutics Corporation

University of Toronto

Kyle Giovanni Battiston

Wendy Alison Naimark

Matthew Alexander John Statham

Ian Charles Parrag

Hans Christian Fischer

Dimitra Louka

Georgios Rizis

Leonard Pinchuk

Roseita Esfand

Provided herein are (e.g., controlled release) compositions for the treatment of acute or chronic diseases or disorders. Described herein are processable opioid conjugates. Also described herein are compositions and methods for the treatment of central nervous system (CNS) diseases or disorders including chronic pain (e.g., cancer pain), acute pain, opioid addiction, alcohol addiction, alcohol dependence, opioid-induced constipation, and narcotic depression. Said compositions and methods comprise opioid agonists and/or opioid antagonists, which demonstrate CNS activity and/or other desirable activities. Injection of said compositions subcutaneously or intraspinally provides therapeutic benefit to individuals suffering from CNS diseases or disorders.

Compositions and methods for the treatment of pain and dependence disorders

The disclosure relates to compounds and compositions for sustained release of ocular therapeutics.

Ocular inserts comprising a covalently linked steroid dimer

Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

Heterodimer compositions and methods for the treatment of ocular disorders

Polar hydrophobic ionic materials and, in particular, polar hydrophobic ionic polyurethanes having a minimum ratio of hydrophobic and anionic components to the remainder of the polymer components are provided that exhibit reduced IgG Fab exposure.

Biomaterial with reduced inflammatory response

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

Dexamethasone prodrug compositions and uses thereof

The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

Growing community of inventors

Toronto, Canada

Kyle Giovanni Battiston